Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niclosamide in Moderate COVID-19 with GI Symptoms
NCT04436458Phase 2Withdrawn
- Sponsor
- Entero Therapeutics, Inc.
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of niclosamide in coronavirus disease 2019 (COVID-19), sponsored by Entero Therapeutics, Inc.. Planned start Jan 2022; status: withdrawn.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04436458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04436458.